The blood–brain barrier (BBB) is impaired by the migration of substantial numbers of leukocytes to the CNS in MS (Larochelle et al., 2011), and miR-146a can suppress NF-κB activity in brain endothelial cells (BECs) by inhibiting nuclear factor of activated T cells 5 (NFAT5), RhoA, IRAK1, and TRAF6 and subsequently negatively regulate the adhesion of leukocytes to BECs in vivo and invitro (Wu et al., 2015). Here, NFAT5 is linked to myeloid sarcoma.